Omny-IRE clinical trial completes enrolment - Cardiac Rhythm News

Biosense Webster completes enrolment of Omny-IRE trial, evaluating Omnypulse platform for mapping and treating paroxysmal atrial fibrillation. The platform combines pulsed field ablation therapy with mapping via Carto 3 system, aiming to provide electrophysiologists with new tools for optimal patient procedures.